Nuance Investments LLC Lowers Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Nuance Investments LLC trimmed its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 9.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 149,413 shares of the medical equipment provider’s stock after selling 15,270 shares during the quarter. Nuance Investments LLC’s holdings in Hologic were worth $10,771,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Benson Investment Management Company Inc. bought a new position in shares of Hologic in the 4th quarter worth $4,832,000. Principal Financial Group Inc. lifted its position in shares of Hologic by 0.6% during the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider’s stock valued at $19,547,000 after buying an additional 1,606 shares during the last quarter. Clean Yield Group grew its position in shares of Hologic by 18.9% in the 4th quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock worth $3,291,000 after buying an additional 7,266 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Hologic by 2.9% during the 3rd quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock worth $2,344,000 after acquiring an additional 800 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Hologic during the third quarter valued at approximately $2,350,000. Institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HOLX. Evercore ISI reduced their price target on Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a research report on Thursday, February 6th. Wolfe Research initiated coverage on Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. Royal Bank of Canada decreased their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research report on Thursday, February 6th. BNP Paribas upgraded shares of Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Finally, Leerink Partnrs downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $84.62.

Hologic Stock Performance

Shares of NASDAQ HOLX opened at $60.80 on Wednesday. Hologic, Inc. has a 1 year low of $60.34 and a 1 year high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The company’s fifty day moving average price is $65.70 and its 200 day moving average price is $73.66. The company has a market capitalization of $13.64 billion, a PE ratio of 19.18, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.